论文信息 - End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). - 字舞流文

End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).

A. Logan | M. Bishop | J. Pagel | A. Mardiros | W. Wierda | R. Jain | O. Oluwole | Yi Lin | A. Ghobadi | M. Arellano | B. Shah | M. Baer | R. Cassaday | W. Donnellan | Jae H. Park | L. Goyal | R. Vezan | T. Shen | H. Holmes | Kristen Marie Carr-O'Dwyer